Concentra Group Holdings Parent (CON) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
6 Aug, 2026Executive summary
Revenue for Q2 2026 increased 10.0% year-over-year to $606.0 million, driven by organic growth and acquisitions.
Net income attributable to the company rose 46.6% to $65.3 million for the quarter, with EPS of $0.51.
Adjusted EBITDA margin improved to 23.3% from 20.9% in the prior year quarter.
Announced leadership transition: Matt DiCanio to become president and CEO, Keith Newton to executive chairman, effective Nov. 1, 2026.
Declared a cash dividend of $0.0625 per share, payable August 28, 2026.
Financial highlights
Q2 2026 revenue: $606.0 million (up 10.0% year-over-year); six-month revenue: $1,175.6 million (up 11.8%).
Net income attributable to the company: $65.3 million for Q2 (up from $44.6 million); $115.8 million for six months (up from $83.5 million).
Adjusted EBITDA: $140.9 million for Q2 (23.3% margin), up 22.5% year-over-year; $261.6 million for six months (22.3% margin).
Free cash flow for six months: $130.9 million, up from $59.1 million year-over-year; Q2 free cash flow: $121.0 million, up 91.6%.
Cash at period end: $158.0 million; net leverage ratio: 2.99x.
Outlook and guidance
Raised FY 2026 guidance: revenue $2.325–$2.375 billion, Adjusted EBITDA $485–$495 million.
Free cash flow expected at $220–$240 million; capital expenditures $70–$80 million.
Net leverage ratio expected to remain below 3.0x.
Sufficient liquidity and borrowing capacity to support operations and growth initiatives.
No formal changes to risk factors or guidance disclosed for the remainder of 2026.
Latest events from Concentra Group Holdings Parent
- Q3 2024 revenue up 3.3% YoY, with stable margins and ongoing expansion across the U.S.CON
Investor presentation14 Jul 2026 - Nova acquisition, strong 2024 results, and 2025 double-digit growth outlook drive expansion.CON
Q4 20248 Jul 2026 - Q1 revenue and EBITDA rose 7.1% and 6.8%, with guidance raised and major acquisitions completed.CON
Q1 20258 Jul 2026 - Industry leader with $2.16bn revenue, strong margins, and robust growth across diversified channels.CON
Investor presentation30 Jun 2026 - Acquisition doubles onsite clinic size, creating the top U.S. occupational health provider.CON
Investor presentation30 Jun 2026 - Strong 2025 growth, high satisfaction, and disciplined expansion drive robust outlook.CON
44th Annual J.P. Morgan Healthcare Conference29 May 2026 - Q1 2026 saw 13.7% revenue growth, margin gains, and raised full-year guidance.CON
Q1 20268 May 2026 - Director elections, executive pay, and auditor ratification headline a governance-focused proxy.CON
Proxy Filing17 Mar 2026 - Director elections, executive pay, and auditor ratification headline the 2026 proxy.CON
Proxy Filing17 Mar 2026